The Experts below are selected from a list of 204 Experts worldwide ranked by ideXlab platform
Jiying Zhou - One of the best experts on this subject based on the ideXlab platform.
-
neuropathic pain section case report Basilar Type Migraine with coma case reports and literature review
2016Co-Authors: Qin Li, Jiying ZhouAbstract:Background. Basilar-Type Migraine (BTM) is a rare subType of Migraine with aura. Impaired conscious- ness or coma can occur in such patients. Aim. To report two Chinese adolescent patients diagnosed as BTM with coma. Materials and Methods. We describe two Chinese adolescent patients diagnosed with BTM with coma. Literatures of Migraineurs presented with coma were reviewed. Results. The two patients are partially resolved with prophylactic propranolol or valproate therapy. Conclusion. BTM should be considered for any patient presenting with Migraine and coma. Adequate care should be taken to prevent Migraine attacks.
-
headache facial pain section original research article clinical characteristics of Basilar Type Migraine in the neurological clinic of a university hospital
2016Co-Authors: Guomin Ying, Nan Li, Jing Wang, Wangwen Li, Jiying ZhouAbstract:eral visual symptoms 39%, hypacusia 26%, ataxia 26%, dysarthria 22%, bilateral paresthesias 13%, and decreased level of consciousness 13%. Intense emotional stimuli (74%) and sleep disorders (65%) were the most common trigger factors, followed by change in weather, sunshine, cold wind, acute stress, alcohol, and fatigue. Conclusion. Basilar-Type Migraine is an episodic disorder and occurred in 1.5% of patients with headache. More than one-half of patients have their first attack in the second and third decade of life. Trigger factors were common, and patients should be educated to avoid trigger factors.
-
HEADACHE & FACIAL PAIN SECTION Original Research Article Clinical Characteristics of Basilar-Type Migraine in the Neurological Clinic of a University Hospital
2016Co-Authors: Guomin Ying, Nan Li, Jing Wang, Wangwen Li, Jiying ZhouAbstract:eral visual symptoms 39%, hypacusia 26%, ataxia 26%, dysarthria 22%, bilateral paresthesias 13%, and decreased level of consciousness 13%. Intense emotional stimuli (74%) and sleep disorders (65%) were the most common trigger factors, followed by change in weather, sunshine, cold wind, acute stress, alcohol, and fatigue. Conclusion. Basilar-Type Migraine is an episodic disorder and occurred in 1.5% of patients with headache. More than one-half of patients have their first attack in the second and third decade of life. Trigger factors were common, and patients should be educated to avoid trigger factors.
-
clinical characteristics of Basilar Type Migraine in the neurological clinic of a university hospital
Pain Medicine, 2014Co-Authors: Guomin Ying, Nan Li, Jing Wang, Wangwen Li, Jiying ZhouAbstract:Objectives The aim of this study was to investigate the prevalence and clinical characteristics of Basilar-Type Migraine in the neurology outpatient clinic of a university hospital in China. Methods This cross-sectional study was conducted in the neurology outpatient of a tertiary care hospital in Chongqing between January 2010 and December 2011. All consecutive patients citing headache as their chief complaint were asked to complete a face-to-face interview by a qualified headache specialist using a detailed questionnaire for headache. The diagnosis of Basilar-Type Migraine was made according to International Classification of Headache Disorders Second Edition. Results Of the 1,526 headache patients, 23 (1.5%) were diagnosed with Basilar-Type Migraine (19 women, four men). Basilar-Type Migraine occurred in 6.6% (23/348) of patients with Migraine with nonhemiplegic aura. Mean age at onset was 20.3 ± 11.7 years (range 6–49 years). Among these patients, 65% (15/23) reported bilateral pain, 35% (8/23) unilateral pain. The Basilar-Type aura comprised diplopia 52%, vertigo 43%, tinnitus 43%, bilateral visual symptoms 39%, hypacusia 26%, ataxia 26%, dysarthria 22%, bilateral paresthesias 13%, and decreased level of consciousness 13%. Intense emotional stimuli (74%) and sleep disorders (65%) were the most common trigger factors, followed by change in weather, sunshine, cold wind, acute stress, alcohol, and fatigue. Conclusion Basilar-Type Migraine is an episodic disorder and occurred in 1.5% of patients with headache. More than one-half of patients have their first attack in the second and third decade of life. Trigger factors were common, and patients should be educated to avoid trigger factors.
-
Basilar Type Migraine with coma case reports and literature review
Pain Medicine, 2011Co-Authors: Qin Li, Jiying ZhouAbstract:Background. Basilar-Type Migraine (BTM) is a rare subType of Migraine with aura. Impaired consciousness or coma can occur in such patients. Aim. To report two Chinese adolescent patients diagnosed as BTM with coma. Materials and Methods. We describe two Chinese adolescent patients diagnosed with BTM with coma. Literatures of Migraineurs presented with coma were reviewed. Results. The two patients are partially resolved with prophylactic propranolol or valproate therapy. Conclusion. BTM should be considered for any patient presenting with Migraine and coma. Adequate care should be taken to prevent Migraine attacks. * ACM : acute confusional Migraine BAM : Basilar artery Migraine F : female FHM : familial hemiplegic Migraine M : male PBM : psychogenic Basilar Migraine
Matthew S Robbins - One of the best experts on this subject based on the ideXlab platform.
-
pontine infarction as a complication of Basilar Type Migraine status migrainosus p01 093
Neurology, 2013Co-Authors: Sarah E Vollbracht, Matthew S Robbins, Ilya KisterAbstract:OBJECTIVE: To present a patient with Basilar-Type Migraine (BTM) sustaining a pontine infarction during status migrainosus and to discuss the case in the context of the International Classification of Headache Disorders, 2nd Edition (ICHD-2) criteria for migrainous infarction. BACKGROUND: The ICHD-2 defines migrainous infarction as one or more otherwise typical aura symptoms that persist beyond one hour with neuroimaging confirmation of an ischemic infarction in the affected territory. The ICHD-2 criteria exclude patients with new onset aura as well as patients who develop “extra-aural” symptoms at the time of infarction. DESIGN/METHODS: Case report from a tertiary medical center. RESULTS: A 42-year-old woman with BTM whose aura symptoms included vertigo, tinnitus, hypacusis, gait unsteadiness, and disorientation developed her typical constellation of aura symptoms followed by a two-week period of status migrainosus, which she was treating with eletriptan 40 to 80mg mg daily. Several days into the headache phase she experienced acute, maximal-at-onset dysarthria and left face, arm, and leg numbness and weakness. These symptoms minimally improved over several weeks, leaving her with mild residual left-sided sensorimotor deficits and dysarthria. She had also been taking estrogen-containing oral contraception. MRI and MRA of the brain revealed a pontine ischemic lesion and Basilar artery fenestration. CONCLUSIONS: This patient presents a diagnostic dilemma, since her stroke symptoms were not part of her typical aura syndrome and therefore does not fulfill ICHD-2 criteria for migrainous infarction. These restrictions on what constitutes a bona fide migrainous infarction may improve specificity at the expense of sensitivity, potentially underestimating the role of Migraine in stroke etiology. Disclosure: Dr. Vollbracht9s family owns stock and/or stock options in Allergan, Inc. Dr. Robbins has nothing to disclose. Dr. Kister has nothing to disclose.
-
Primary headache disorders and neuro-ophthalmologic manifestations.
Eye and brain, 2012Co-Authors: Daniel Schwartz, Matthew S RobbinsAbstract:Headache is an extraordinarily common complaint presenting to medical practitioners in all arenas and specialties, particularly primary care physicians, neurologists, and ophthalmologists. A wide variety of headache disorders may manifest with a myriad of neuro-ophthalmologic symptoms, including orbital pain, disturbances of vision, aura, photophobia, lacrimation, conjunctival injection, ptosis, and other manifestations. The differential diagnosis in these patients is broad and includes both secondary, or symptomatic, and primary headache disorders. Awareness of the headache patterns and associated symptoms of these various disorders is essential to achieve the correct diagnosis. This paper reviews the primary headache disorders that prominently feature neuro-ophthalmologic manifestations, including Migraine, the trigeminal autonomic cephalalgias, and hemicrania continua. Migraine variants with prominent neuro-ophthalmologic symptoms including aura without headache, Basilar-Type Migraine, retinal Migraine, and ophthalmoplegic Migraine are also reviewed. This paper focuses particularly on the symptomatology of these primary headache disorders, but also discusses their epidemiology, clinical features, and treatment.
-
cacna1a nonsense mutation is associated with Basilar Type Migraine and episodic ataxia Type 2
Headache, 2009Co-Authors: Matthew S Robbins, Richard B Lipton, Emma Laureta, Brian M GrosbergAbstract:Mutations in the CACNA1A gene on chromosome 19 have been associated with a variety of clinical disorders, including familial hemiplegic Migraine Type 1 and episodic ataxia Type 2 (EA2). We report a patient with 2 distinct attack Types, one representing EA2 and the other, Basilar-Type Migraine. Genetic testing revealed a novel nonsense mutation in the CACNA1A gene at codon position 583. Treatment with acetazolamide relieved both Types of attacks. We hypothesize that the CACNA1A gene mutation may contribute to both typical EA2 and typical Basilar-Type Migraine, extending the spectrum of clinical manifestations associated with CACNA1A mutations.
-
CACNA1A Nonsense Mutation is Associated With Basilar‐Type Migraine and Episodic Ataxia Type 2
Headache, 2009Co-Authors: Matthew S Robbins, Richard B Lipton, Emma Laureta, Brian M GrosbergAbstract:Mutations in the CACNA1A gene on chromosome 19 have been associated with a variety of clinical disorders, including familial hemiplegic Migraine Type 1 and episodic ataxia Type 2 (EA2). We report a patient with 2 distinct attack Types, one representing EA2 and the other, Basilar-Type Migraine. Genetic testing revealed a novel nonsense mutation in the CACNA1A gene at codon position 583. Treatment with acetazolamide relieved both Types of attacks. We hypothesize that the CACNA1A gene mutation may contribute to both typical EA2 and typical Basilar-Type Migraine, extending the spectrum of clinical manifestations associated with CACNA1A mutations.
-
brief communications cacna1a nonsense mutation is associated with Basilar Type Migraine and episodic ataxia Type 2
2009Co-Authors: Matthew S Robbins, Richard B Lipton, Emma Laureta, Brian M GrosbergAbstract:Mutations in the CACNA1A gene on chromosome 19 have been associated with a variety of clinical disorders, including familial hemiplegic Migraine Type 1 and episodic ataxia Type 2 (EA2). We report a patient with 2 distinct attack Types, one representing EA2 and the other, Basilar-Type Migraine. Genetic testing revealed a novel nonsense mutation in the CACNA1A gene at codon position 583. Treatment with acetazolamide relieved both Types of attacks. We hypothesize that the CACNA1A gene mutation may contribute to both typical EA2 and typical Basilar-Type Migraine, extending the spectrum of clinical manifestations associated with CACNA1A mutations.
Brian M Grosberg - One of the best experts on this subject based on the ideXlab platform.
-
cacna1a nonsense mutation is associated with Basilar Type Migraine and episodic ataxia Type 2
Headache, 2009Co-Authors: Matthew S Robbins, Richard B Lipton, Emma Laureta, Brian M GrosbergAbstract:Mutations in the CACNA1A gene on chromosome 19 have been associated with a variety of clinical disorders, including familial hemiplegic Migraine Type 1 and episodic ataxia Type 2 (EA2). We report a patient with 2 distinct attack Types, one representing EA2 and the other, Basilar-Type Migraine. Genetic testing revealed a novel nonsense mutation in the CACNA1A gene at codon position 583. Treatment with acetazolamide relieved both Types of attacks. We hypothesize that the CACNA1A gene mutation may contribute to both typical EA2 and typical Basilar-Type Migraine, extending the spectrum of clinical manifestations associated with CACNA1A mutations.
-
CACNA1A Nonsense Mutation is Associated With Basilar‐Type Migraine and Episodic Ataxia Type 2
Headache, 2009Co-Authors: Matthew S Robbins, Richard B Lipton, Emma Laureta, Brian M GrosbergAbstract:Mutations in the CACNA1A gene on chromosome 19 have been associated with a variety of clinical disorders, including familial hemiplegic Migraine Type 1 and episodic ataxia Type 2 (EA2). We report a patient with 2 distinct attack Types, one representing EA2 and the other, Basilar-Type Migraine. Genetic testing revealed a novel nonsense mutation in the CACNA1A gene at codon position 583. Treatment with acetazolamide relieved both Types of attacks. We hypothesize that the CACNA1A gene mutation may contribute to both typical EA2 and typical Basilar-Type Migraine, extending the spectrum of clinical manifestations associated with CACNA1A mutations.
-
brief communications cacna1a nonsense mutation is associated with Basilar Type Migraine and episodic ataxia Type 2
2009Co-Authors: Matthew S Robbins, Richard B Lipton, Emma Laureta, Brian M GrosbergAbstract:Mutations in the CACNA1A gene on chromosome 19 have been associated with a variety of clinical disorders, including familial hemiplegic Migraine Type 1 and episodic ataxia Type 2 (EA2). We report a patient with 2 distinct attack Types, one representing EA2 and the other, Basilar-Type Migraine. Genetic testing revealed a novel nonsense mutation in the CACNA1A gene at codon position 583. Treatment with acetazolamide relieved both Types of attacks. We hypothesize that the CACNA1A gene mutation may contribute to both typical EA2 and typical Basilar-Type Migraine, extending the spectrum of clinical manifestations associated with CACNA1A mutations.
Erika Paradiso - One of the best experts on this subject based on the ideXlab platform.
-
A Double-Blind, Dose Comparison Study of Topiramate for Prophylaxis of Basilar-Type Migraine in Children: A Pilot Study
Headache, 2007Co-Authors: Donald W. Lewis, Erika ParadisoAbstract:Background.— Basilar-Type Migraine (BM) is the most common Migraine “variant,” representing 3-19% of Migraine in children.BMis characterized by attacks of dizziness, vertigo, visual disturbances, ataxia, and/or diplopia, followed by Migraine headache. Objective.— The objective of this study is to assess the efficacy and safety of topiramate for prophylaxis of BM in children and adolescents (6-18 years). Design.— Outpatient, double-blind, parallel-group, dose comparison study with 2 phases: prerandomization (screening/washout and 4-week prospective baseline) and 12-week double blind (titration and maintenance). Methods.— Following consent and assent, subjects with BMs, as defined by the International Classification of Headache Disorders (second edition), and ≥4 Migraines/month were randomized to receive either 25 mg per day or 100 mg per day of topiramate in a 1 : 1 ratio. Results.— Fourteen children (4 boys, 10 girls) completed the double-blind phase (7 in the 25-mg group and 7 in the 100-mg group). During the prospective baseline, the mean headache frequency of the combined group “all Migraines” per month was 4.5/month (25 mg) and 4.8/month (100 mg). Average duration of Migraine was 5.5 hours (25 mg) and 5.0 hours (100 mg) and average mean pain (5-point faces scale) was 3.3 for both (25 mg 100 mg). The reduction in median monthly Migraine rate during the double-blind treatment phase relative to baseline was 2.9 (64.4%) and 3.6 (75.0%) for the 25-mg and 100-mg topiramate-treated groups, respectively (P
-
a double blind dose comparison study of topiramate for prophylaxis of Basilar Type Migraine in children a pilot study
Headache, 2007Co-Authors: Donald W. Lewis, Erika ParadisoAbstract:Background.— Basilar-Type Migraine (BM) is the most common Migraine “variant,” representing 3-19% of Migraine in children.BMis characterized by attacks of dizziness, vertigo, visual disturbances, ataxia, and/or diplopia, followed by Migraine headache. Objective.— The objective of this study is to assess the efficacy and safety of topiramate for prophylaxis of BM in children and adolescents (6-18 years). Design.— Outpatient, double-blind, parallel-group, dose comparison study with 2 phases: prerandomization (screening/washout and 4-week prospective baseline) and 12-week double blind (titration and maintenance). Methods.— Following consent and assent, subjects with BMs, as defined by the International Classification of Headache Disorders (second edition), and ≥4 Migraines/month were randomized to receive either 25 mg per day or 100 mg per day of topiramate in a 1 : 1 ratio. Results.— Fourteen children (4 boys, 10 girls) completed the double-blind phase (7 in the 25-mg group and 7 in the 100-mg group). During the prospective baseline, the mean headache frequency of the combined group “all Migraines” per month was 4.5/month (25 mg) and 4.8/month (100 mg). Average duration of Migraine was 5.5 hours (25 mg) and 5.0 hours (100 mg) and average mean pain (5-point faces scale) was 3.3 for both (25 mg 100 mg). The reduction in median monthly Migraine rate during the double-blind treatment phase relative to baseline was 2.9 (64.4%) and 3.6 (75.0%) for the 25-mg and 100-mg topiramate-treated groups, respectively (P < .001). The reduction in median monthly BM rate during the double-blind treatment phase relative to baseline was 2.5 (74.24%) and 2.3 (82.8%) for the 25-mg and 100-mg topiramate-treated groups, respectively. The overall reduction in BM attacks reduced from 2.84/month to 0.59/month (79.2%; P < .0042). Overall, 86% of patients responded with a greater than 50% reduction in Migraine frequency (100%, 25 mg and 71%, 100 mg). Mean reduction in Migraine duration was 18 minutes (25 mg) and 89 minutes (100 mg). There was no significant difference in Migraine severity between the 2 groups. Parent Global Assessment was “very much” or “much improved” in 6 of 7 (25 mg) and 3 of 7 (100 mg) patients. Migraine disability as measured by PedMidas© reduced from moderate to no disability (P < .001). There were no serious adverse events. Conclusions.— Preventive therapy with topiramate resulted in reducing the overall Migraine frequency and the frequency of attacks of BM at both 25 mg and 100 mg doses relative to the historical baseline and prospective baseline periods. The 2 treatment groups resulted in comparable outcomes.
Neil Cherian - One of the best experts on this subject based on the ideXlab platform.
-
acute treatment of Basilar Type Migraine with greater occipital nerve blockade
Headache, 2010Co-Authors: Eric P Baron, Stewart J Tepper, Maryann Mays, Neil CherianAbstract:Basilar-Type Migraine (BTM) precludes use of Migraine-specific medications such as triptans and ergots based on concerns originating from the vascular theory of Migraine, although data supporting this contraindication are lacking. Availability of effective treatments for acute BTM is limited. We report a case of BTM aborted with greater occipital nerve (GON) blockade given in the setting of prominent suboccipital tenderness. GON blockade may provide an additional option in acute management of BTM. It may be particularly useful when associated with prominent ipsilateral suboccipital tenderness.
-
Acute Treatment of Basilar‐Type Migraine With Greater Occipital Nerve Blockade
Headache, 2010Co-Authors: Eric P Baron, Stewart J Tepper, Maryann Mays, Neil CherianAbstract:Basilar-Type Migraine (BTM) precludes use of Migraine-specific medications such as triptans and ergots based on concerns originating from the vascular theory of Migraine, although data supporting this contraindication are lacking. Availability of effective treatments for acute BTM is limited. We report a case of BTM aborted with greater occipital nerve (GON) blockade given in the setting of prominent suboccipital tenderness. GON blockade may provide an additional option in acute management of BTM. It may be particularly useful when associated with prominent ipsilateral suboccipital tenderness.